CytomX Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 11, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 11, 2024
CTMX$1.98-9.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets
| December 31, | December 31, | |
|---|---|---|
| 2023 | 2022 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $17,171 | $193,650 |
| Short-term investments | 157,338 | — |
| Accounts receivable | 3,432 | 35,986 |
| Prepaid expenses and other current assets | 4,995 | 7,466 |
| Total current assets | 182,936 | 237,102 |
| Property and equipment, net | 3,958 | 5,072 |
| Intangible assets, net | 729 | 875 |
| Goodwill | 949 | 949 |
| Restricted cash | 917 | 917 |
| Operating lease right-of-use asset | 12,220 | 15,949 |
| Other assets | 83 | 27 |
| Total assets | $201,792 | $260,891 |
| Liabilities and Stockholders' Deficit | ||
| Current liabilities: | ||
| Accounts payable | $1,458 | $2,809 |
| Accrued liabilities | 17,599 | 24,450 |
| Operating lease liabilities - short term | 4,589 | 4,082 |
| Deferred revenues, current portion | 132,267 | 121,267 |
| Total current liabilities | 155,913 | 152,608 |
| Deferred revenue, net of current portion | 80,048 | 180,059 |
| Operating lease liabilities - long term | 9,385 | 13,975 |
| Other long-term liabilities | 3,893 | — |
| Total liabilities | 249,239 | 346,642 |
| Commitments and contingencies (Note 10) | ||
| Stockholders' deficit | ||
| Convertible preferred stock, $0.00001 par value; 10,000,000 shares authorized and no shares issued and outstanding | — | — |
| Common stock, $0.00001 par value; 150,000,000 shares authorized, and 67,310,838 and 66,228,046 shares issued and outstanding at December 31, 2023 and 2022, respectively | 1 | 1 |
| Additional paid-in capital | 675,905 | 637,117 |
| Accumulated other comprehensive income | 95 | 10 |
| Accumulated deficit | (723,448) | (722,879) |
| Total stockholders' deficit | (47,447) | (85,751) |
| Total liabilities and stockholders' deficit | $201,792 | $260,891 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.